• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Phibro Animal Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/27/25 5:08:02 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PAHC alert in real time by email
    0001069899false00010698992025-08-272025-08-27

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    ​

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(D) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): August 27, 2025

    Phibro Animal Health Corporation

    (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

    ​

    Delaware

        

    001-36410

        

    13-1840497

    (State or other jurisdiction of
    incorporation)

     

    (Commission File Number)

     

    (IRS Employer Identification No.)

    ​

    Glenpointe Centre East, 3rd Floor

    300 Frank W. Burr Boulevard, Suite 21

    Teaneck, New Jersey 07666-6712

    (Address of Principal Executive Offices, including Zip Code)

    ​

    (201) 329-7300

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading Symbol(s)

        

    Name of each exchange on which registered

    Class A Common Stock, $0.0001 par value per share

    ​

    PAHC

    ​

    NASDAQ Stock Market

    ​

    Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ITEM 2.02     RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

    On August 27, 2025, Phibro Animal Health Corporation issued a press release announcing its operating results for the fourth quarter and fiscal year ended June 30, 2025 and its financial guidance for the fiscal year ending June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    ITEM 9.01     FINANCIAL STATEMENTS AND EXHIBITS.

    (d) Exhibits

    Exhibit
    Number

        

    Description

    99.1

     

    Press Release, dated August 27, 2025.

    ​

    ​

    ​

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    ​

    PHIBRO ANIMAL HEALTH CORPORATION

    Registrant

    ​

    ​

    Date: August 27, 2025

    ​

    ​

    ​

    ​

    By: 

    /s/ Judith Weinstein

    ​

    Name:

    Judith Weinstein

    ​

    Title:

    Senior Vice President, General Counsel and Corporate Secretary

    ​

    ​

    ​

    Get the next $PAHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAHC

    DatePrice TargetRatingAnalyst
    7/7/2025$35.00Neutral → Overweight
    Analyst
    6/16/2025$24.00Underperform → Neutral
    BNP Paribas Exane
    9/10/2024$22.00Neutral
    JP Morgan
    12/7/2023$9.00Underperform
    Exane BNP Paribas
    12/21/2022$18.00Buy
    ROTH Capital
    7/25/2022$22.00Equal Weight → Underweight
    Barclays
    1/10/2022$23.00Underweight → Equal-Weight
    Barclays
    11/18/2021$23.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $PAHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phibro Animal Health Corporation Announces Licensing Agreement with Lighthouse Pharmaceuticals, Inc. for Innovative Periodontal Health Asset for Dogs

    Phibro Animal Health Corporation (NASDAQ:PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset targeting periodontal health in companion animals. This agreement grants Phibro exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma's proprietary compound for canine periodontal care. The compound represents a promising advancement in veterinary dental health, addressing a widespread and often under-treated condition in dogs. "We are excited to partner with Lighthouse Pharma to help develop and commercialize a new solution for periodontal dise

    10/9/25 4:30:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Participate at Morgan Stanley Annual Global Healthcare Conference

    Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 9, 2025, at 12:20 PM ET at the Sheraton New York Times Square Hotel. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. W

    9/2/25 4:00:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5 million, or 39% Net income of $17.2 million, an increase of $16.5 million Diluted earnings per share of $0.42, an increase of $0.40 Adjusted EBITDA of $50.0 million, an increase of $16.5 million, or 49% Adjusted net income of $23.2 million, an increase of $6.6 million, or 39% Adjusted

    8/27/25 4:57:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phibro Animal Health upgraded by Analyst with a new price target

    Analyst upgraded Phibro Animal Health from Neutral to Overweight and set a new price target of $35.00

    7/7/25 8:10:48 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Phibro Animal Health from Underperform to Neutral and set a new price target of $24.00

    6/16/25 8:16:19 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan initiated coverage on Phibro Animal Health with a new price target

    JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00

    9/10/24 7:55:45 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Corcoran E Thomas bought $110,500 worth of shares (5,000 units at $22.10), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    2/26/25 4:15:17 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Corcoran E Thomas bought $100,100 worth of shares (5,000 units at $20.02), increasing direct ownership by 25% to 25,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/6/24 4:34:30 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Bendheim Jack sold $834,412 worth of shares (20,664 units at $40.38) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    10/1/25 4:10:25 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack sold $282,732 worth of shares (7,022 units at $40.26) and converted options into 30,000 shares (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/22/25 6:32:03 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack sold $857,313 worth of shares (21,120 units at $40.59) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/11/25 8:56:36 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Phibro Animal Health Corporation

    DEFA14A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    9/19/25 4:15:06 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Phibro Animal Health Corporation

    DEF 14A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    9/19/25 4:10:42 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    8/27/25 5:08:02 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Leadership Updates

    Live Leadership Updates

    View All

    Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.

    1/23/25 4:45:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TerraCycle Appoints New Chief Financial Officer to Global Leadership Team

    Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ --­ TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at

    9/6/23 12:20:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Announces the Appointment of Alejandro Bernal to Its Board of Directors and Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and

    2/6/23 4:15:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

    SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/15/24 4:15:40 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/14/24 12:51:31 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/12/24 4:55:22 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Financials

    Live finance-specific insights

    View All

    Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5 million, or 39% Net income of $17.2 million, an increase of $16.5 million Diluted earnings per share of $0.42, an increase of $0.40 Adjusted EBITDA of $50.0 million, an increase of $16.5 million, or 49% Adjusted net income of $23.2 million, an increase of $6.6 million, or 39% Adjusted

    8/27/25 4:57:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2025 Results

    Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its fourth quarter and fiscal year 2025 financial results on Wednesday, August 27, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 28, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of

    8/20/25 4:00:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 24, 2025, to stockholders of record at the close of business on September 3, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please v

    7/29/25 4:10:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care